Latest FDA Stories
BOULDER, Col., March 6, 2015 /PRNewswire/ -- NEBA Health announces today that Brain and Behavior has published validation results for the first biomarker cleared by FDA to assist a
New Therapy Will Harness the Power of Patients' Own Immune Systems to Fight Lung Cancer WASHINGTON, March 5, 2015 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's leading lung
7-9 AUGUST 2015 @ TATMADAW HALL, YANGON, Myanmar Pharmaceutical Exhibition, Myanmar Medical Exhibition, Myanmar Medical Conference, Myanmar Healthcare Conference, Myanmar Medical Equipment Show,
Sports Nutrition Ingredient, Nitrosigine, Supplies Bodybuilding Expo with Bicep Pump Challenge Columbus, Ohio (PRWEB) March 04, 2015 Nitrosigine®,
The FDA is requiring the manufacturers of low testosterone therapy drugs to warn patients that the medications may increase the risk for heart attacks and strokes. New
FDA investigators generally know within four hours of an inspection whether a manufacturer’s in trouble or not.
NuMale Medical Center Founder and Chief Medical Officer Dr. Christopher Asandra, M.D.
- Initial Hepatoren® Phase II study results NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
HORSHOLM, Denmark, March 3, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2014.
- Emitting flashes of light; glittering.